PDCD1 and head and neck squamous cell carcinoma: Sacco AG et al reported that the efficacy and safety of pembrolizumab plus cetuximab in patients with R/M HNSCC who with no previous PD-1, PD-L1, or EGFR inhibition after recurrent or metastatic.